Network pharmacology and single-cell sequencing analysis of gastrodin in anticancer effects against colorectal cancer by regulating key target genes and the tumor immune microenvironment.
4 affiliations
- 1Zhongshan People's Hospital, Zhongshan, China. Electronic address: [email protected].
- 2Hunan Provincial Key Laboratory of Novel Antibody Drugs and Their Intelligent Transportation Systems, Hunan Provincial Key Laboratory of Synthetic Biology Research of Traditional Chinese Medicines, School of Medical Information and Engineering, Hunan Medical College, Huaihua, China.
- 3Zhongshan People's Hospital, Zhongshan, China.
- 4Zhongshan People's Hospital, Zhongshan, China. Electronic address: [email protected].
Abstract
Background
Gastrodin is a natural compound with anti-inflammatory, antioxidant, and antitumor activities; however, its therapeutic role and molecular mechanisms in colorectal cancer (CRC) remain unclear. In this study, we explored the anti-CRC mechanisms of gastrodin through integrated bioinformatics and experimental validation.Methods
The potential targets of gastrodin were obtained from public databases. Transcriptomic data of CRC were retrieved from TCGA and GEO datasets, and the differentially expressed genes were screened. The CRC-related genes were subjected to gene-set variation analysis and weighted gene co-expression network analysis, and the core genes were identified by the LASSO regression, support vector machine, and random forest algorithms, followed by SHAP analysis. Single-cell RNA sequencing (scRNA-seq), immune infiltration analysis, consensus clustering, molecular docking, and in vitro experiments were further performed.Results
A total of 628 potential gastrodin targets and 15 overlapping CRC-related genes were identified. Five core hub genes, including NFE2L3, UBE2S, CA9, CCNB1, and CFD, were screened, among which NFE2L3 showed the highest SHAP importance score. The scRNA-seq data indicated cell-type-specific expression patterns of these genes in CRC tissues. Immune infiltration analysis further suggested that gastrodin may regulate the CRC immune microenvironment by regulating the activated B cells, activated CD4⁺ T cells, and other immune cells. Molecular docking revealed favorable binding affinity between gastrodin and the five core proteins. Moreover, NFE2L3 was highly expressed in CRC tissues and cell lines, and its knockdown significantly inhibited the proliferation, migration, and invasion of the tumor cells.Conclusion
Gastrodin may suppress CRC progression by targeting key genes, particularly NFE2L3, and modulating the tumor immune microenvironment. Furthermore, our study has identified the potential biomarkers and therapeutic targets for CRC.
Related
- Quercetin and tumor microenvironment associated pathways in lung cancer: a network pharmacology and in vitro study
- CGRP remodels the acidic microenvironment and promotes pancreatic carcinoma progression by regulating NHE1 and CA9
- Flavonoids in cancer pharmacology: molecular mechanisms, tumor microenvironment regulation, and drug resistance
- Is the cardio-immune microenvironment a convergent hub of cardiovascular toxicity across novel anticancer therapies?
- XDH Inhibits the Progression of Colorectal Cancer via Regulating Ferritinophagy Signaling.
BibTeX
@article{minjun2026network,
title = {{Network pharmacology and single-cell sequencing analysis of gastrodin in anticancer effects against colorectal cancer by regulating key target genes and the tumor immune microenvironment.}},
author = {Zou Minjun and Xiaojun Dong and Zheng Yuting and Liu Zhishang},
journal = {Translational oncology},
year = {2026},
month = oct,
doi = {10.1016/j.tranon.2026.103076},
url = {https://europepmc.org/article/MED/42879954},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Network pharmacology and single-cell sequencing analysis of gastrodin in anticancer effects against colorectal cancer by regulating key target genes and the tumor immune microenvironment.
AU - Zou Minjun
AU - Xiaojun Dong
AU - Zheng Yuting
AU - Liu Zhishang
PY - 2026
DA - 2026/10/15
JO - Translational oncology
DO - 10.1016/j.tranon.2026.103076
UR - https://europepmc.org/article/MED/42879954
AB - Background Gastrodin is a natural compound with anti-inflammatory, antioxidant, and antitumor activities; however, its therapeutic role and molecular mechanisms in colorectal cancer (CRC) remain unclear. In this study, we explored the anti-CRC mechanisms of gastrodin through integrated bioinformatics and experimental validation.Methods The potential targets of gastrodin were obtained from public databases. Transcriptomic data of CRC were retrieved from TCGA and GEO datasets, and the differentially expressed genes were screened. The CRC-related genes were subjected to gene-set variation analysis and weighted gene co-expression network analysis, and the core genes were identified by the LASSO regression, support vector machine, and random forest algorithms, followed by SHAP analysis. Single-cell RNA sequencing (scRNA-seq), immune infiltration analysis, consensus clustering, molecular docking, and in vitro experiments were further performed.Results A total of 628 potential gastrodin targets and 15 overlapping CRC-related genes were identified. Five core hub genes, including NFE2L3, UBE2S, CA9, CCNB1, and CFD, were screened, among which NFE2L3 showed the highest SHAP importance score. The scRNA-seq data indicated cell-type-specific expression patterns of these genes in CRC tissues. Immune infiltration analysis further suggested that gastrodin may regulate the CRC immune microenvironment by regulating the activated B cells, activated CD4⁺ T cells, and other immune cells. Molecular docking revealed favorable binding affinity between gastrodin and the five core proteins. Moreover, NFE2L3 was highly expressed in CRC tissues and cell lines, and its knockdown significantly inhibited the proliferation, migration, and invasion of the tumor cells.Conclusion Gastrodin may suppress CRC progression by targeting key genes, particularly NFE2L3, and modulating the tumor immune microenvironment. Furthermore, our study has identified the potential biomarkers and therapeutic targets for CRC.
SN - 1936-5233
ER -